Edgewise Therapeutics (EWTX) – Research Analysts’ Recent Ratings Changes

Edgewise Therapeutics (NASDAQ: EWTX) has recently received a number of price target changes and ratings updates:

• 7/20/2026 – Edgewise Therapeutics had its “outperform” rating reaffirmed by Evercore Inc. They now have a $55.00 price target on the stock.
• 7/17/2026 – Edgewise Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Edgewise Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $51.00 price target on the stock.
• 7/6/2026 – Edgewise Therapeutics had its price target raised by Guggenheim from $41.00 to $51.00. They now have a “buy” rating on the stock.
• 6/17/2026 – Edgewise Therapeutics had its price target raised by Royal Bank Of Canada from $48.00 to $59.00. They now have an “outperform” rating on the stock.
• 6/17/2026 – Edgewise Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $20.00 to $32.00. They now have a “neutral” rating on the stock.
• 6/16/2026 – Edgewise Therapeutics was given a new $52.00 price target by Leerink Partners.
• 6/16/2026 – Edgewise Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 6/2/2026 – Edgewise Therapeutics had its price target lowered by Royal Bank Of Canada from $50.00 to $48.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Edgewise Therapeutics had its price target raised by HC Wainwright from $42.00 to $45.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Edgewise Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $66.00 price target on the stock.
• 6/1/2026 – Edgewise Therapeutics had its price target raised by Wedbush from $46.00 to $52.00. They now have an “outperform” rating on the stock.

Insider Activity

In related news, insider Alan J. Russell sold 200,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the completion of the sale, the insider owned 24,555 shares of the company’s stock, valued at approximately $967,712.55. This represents a 89.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Joanne M. Donovan sold 50,000 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the sale, the chief marketing officer owned 4,367 shares of the company’s stock, valued at approximately $168,435.19. The trade was a 91.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 255,230 shares of company stock worth $9,974,147. Insiders own 21.30% of the company’s stock.

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.